The PROGRESS is an investigator-initiated, multicentre, randomized, trial comparing
anticoagulation, which is the currently most frequently used treatment, alone, versus
transjugular intrahepatic portosystemic shunt (TIPS) combined with anticoagulation, in
patients presenting with recent obstructive portal vein thrombosis (ROPVT). The rationale of
this study is to significantly increase the proportion of patients that achieve a complete or
partial recanalization of the portal vein. The intervention of this study consists in TIPS
deployment and catheter based clot removal in addition to anticoagulation. The investigators
retain that this intervention will increase the proportion of patients with an open portal
vein from 38% with anticoagulation alone to 83% with anticoagulation and TIPS after 6 months.
Both anticoagulant therapy and clot removal/TIPS are treatments that are currently available
and accepted indications for the treatment of ROPVT. Anticoagulation will be performed with
unfractioned heparin or low molecular weight heparin initially and with vitamin K antagonists
in the long term. The investigators plan to collect blood for biobanking at the time of
inclusion and after 6 months. Blood samples for a biobank will be collected.